AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Zapping eyes with tiny currents to fight vision loss
Disease control Recruiting nowThis study is testing whether a gentle electrical current applied near the eye can help slow vision loss from dry age-related macular degeneration (AMD). About 100 participants with intermediate to advanced dry AMD will use the device at home for 11 months, with some receiving a …
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New pill tested to fight leading cause of vision loss
Disease control Recruiting nowThis is the first human study testing a new oral medication called ABF-101 for age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The study will check if the drug is safe and how it moves through the body in 68 healthy volunteers and people wi…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE1 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC